|
1
|
Chen W, Zheng R, Zhang S, Zhao P, Zeng H,
Zou X and He J: Annual report on status of cancer in China, 2010.
Chin J Cancer Res. 26:48–58. 2014.PubMed/NCBI
|
|
2
|
Rossi RE, Massironi S, Conte D and
Peracchi M: Therapy for metastatic pancreatic neuroendocrine
tumors. Ann Transl Med. 2:82014.PubMed/NCBI
|
|
3
|
Arslan C and Yalcin Y: Current and future
systemic treatment options in metastatic pancreatic cancer. J
Gastrointest Oncol. 5:280–295. 2014.PubMed/NCBI
|
|
4
|
Rozengurt E: Mechanistic target of
rapamycin (mTOR): A point of convergence in the action of
insulin/IGF-1 and G protein-coupled receptor agonists in pancreatic
cancer cells. Front Physiol. 5:3572014. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Liu J, Song R and Cui M: Numerical
simulation on hydromechanical coupling in porous media adopting
three-dimensional pore-scale model. ScientificWorldJournal.
2014:1412062014.
|
|
6
|
Costello E and Neoptolemos JP: Pancreatic
cancer in 2010: New insights for early intervention and detection.
Nat Rev Gastroenterol Hepatol. 8:71–73. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Hidalgo M: Pancreatic Cancer. N Engl J
Med. 362:1605–1617. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Ducreux M, Boige V and Malka D: Treatment
of advanced pancreatic cancer. Semin Oncol. 34 2 Suppl 1:S25–S30.
2007. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Von Hoff DD, Ervin T, Arena FP, Chiorean
EG, Infante J, Moore M, Seay T, Tjulandin SA, Ma WW, Saleh MN, et
al: Increased survival in pancreatic cancer with nab-paclitaxel
plus gemcitabine. N Engl J Med. 369:1691–1703. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Blaszkowsky L: Treatment of advanced and
metastatic pancreatic cancer. Front Biosci. 3:E214–E225. 1998.
View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Bartel DP: MicroRNAs: Genomics,
biogenesis, mechanism, and function. Cell. 116:281–297. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Song B, Zhang C, Li G, Jin G and Liu C:
MiR-940 inhibited pancreatic ductal adenocarcinoma growth by
targeting MyD88. Cell Physiol Biochem. 35:1167–1177. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Ambros V: MicroRNAs: Tiny regulators with
great potential. Cell. 107:823–826. 2011. View Article : Google Scholar
|
|
14
|
Lu J, Getz G, Miska EA, Alvarez-Saavedra
E, Lamb J, Peck D, Sweet-Cordero A, Ebert BL, Mak RH, Ferrando AA,
Downing JR, et al: MicroRNA expression profiles classify human
cancers. Nature. 435:834–838. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Song W, Li Q and Wang L and Wang L:
Modulation of FoxO1 expression by miR-21 to promote growth of
pancreatic ductal adenocarcinoma. Cell Physiol Biochem. 35:184–190.
2015. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Lee RC, Feinbaum RL and Ambros V: The
C.elegans heterochronic gene lin-4 encodes small RNAs with
antisense complementarity to lin-14. Cell. 75:843–854. 1993.
View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Shenouda SK and Alahari SK: MicroRNA
function in cancer: Oncogene or a tumor suppressor? Cancer
Metastasis Rev. 28:369–378. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Iorio MV and Croce CM: MicroRNAs in
cancer: Small molecules with a huge impact. J Clin Oncol.
27:5848–5856. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Palumbo S, Miracco C, Pirtoli L and
Comincini S: Emerging roles of microRNA in modulating cell-death
processes in malignant glioma. J Cell Physiol. 229:277–286. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Ghosh A and Berger A: Opioids, adjuvants,
and interventional options for pain management of symptomatic
metastases. Ann Palliat Med. 3:172–191. 2014.PubMed/NCBI
|
|
21
|
Francis T, Graf A, Hodges K, Kennedy L,
Hargrove L, Price M, Kearney K and Francis H: Histamine regulation
of pancreatitis and pancreatic cancer: A review of recent findings.
Hepatobiliary Surg Nutr. 2:216–226. 2013.PubMed/NCBI
|
|
22
|
Wang J, Paris PL, Chen J, Ngo V, Yao H,
Frazier ML, Killary AM, Liu CG, Liang H, Mathy C, et al: Next
generation sequencing of pancreatic cyst fluid microRNAs from low
grade-benign and high grade-invasive lesions. Cancer Lett.
356:404–409. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Wang J, Raimondo M, Guha S, Chen J, Diao
L, Dong X, Wallace MB, Killary AM, Frazier ML, Woodward TA, et al:
Circulating microRNAs in pancreatic juice as candidate biomarkers
of pancreatic cancer. J Cancer. 5:696–705. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Tan X, Zhou L, Wang H, Yang Y, Sun Y, Wang
Z, Zhang X, Gao F and Li H: Differential expression profiles of
microRNAs in highly and weakly invasive and metastatic pancreatic
cancer cells. Oncol Lett. (In Press).
|
|
25
|
Egami H, Takiyama Y, Cano M, Houser WH and
Pour PM: Establishment of hamster pancreatic ductal carcinoma cell
line (PC-1) producing blood group-related antigens. Carcinogenesis.
10:861–869. 1989. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Egami H, Tomioka T, Tempero M, Kay D and
Pour PM: Development of intrapancreatic transplantable model of
pancreatic duct adenocarcinoma in Syrian golden hamsters. Am J
Pathol. 138:557–561. 1991.PubMed/NCBI
|
|
27
|
Giaginis C, Damaskos C, Koutsounas I,
Zizi-Serbetzoglou A, Tsoukalas N, Patsouris E, Kouraklis G and
Theocharis S: Histone deacetylase (HDAC)-1, −2, −4 and −6
expression in human pancreatic adenocarcinoma: Associations with
clinicopathological parameters, tumor proliferative capacity and
patients' survival. BMC Gastroenterol. 15:1482015. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
de Ruijter AJ, van Gennip AH, Caron HN,
Kemp S and van Kuilenburg AB: Histone deacetylases (HDACs):
Characterization of the classical HDAC family. Biochem J.
370:737–749. 2013. View Article : Google Scholar
|
|
29
|
Marks P, Rifkind RA, Richon VM, Breslow R,
Miller T and Kelly WK: Histone deacetylases and cancer: Causes and
therapies. Nat Rev Cancer. 1:194–202. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Seigneurin-Berny D, Verdel A, Curtet S,
Lemercier C, Garin J, Rousseaux S and Khochbin S: Identification of
components of the murine histone deacetylase 6 complex: Link
between acetylation and ubiquitination signaling pathways. Mol Cell
Biol. 21:8035–8044. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Hubbert C, Guardiola A, Shao R, Kawaguchi
Y, Ito A, Nixon A, Yoshida M, Wang XF and Yao TP: HDAC6 is a
microtubule-associated deacetylase. Nature. 417:455–458. 2002.
View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Gao YS, Hubbert CC, Lu J, Lee YS, Lee JY
and Yao TP: Histone deacetylase 6 regulates growth factor-induced
actin remodeling and endocytosis. Mol Cell Biol. 27:8637–8647.
2007. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Zhang X, Yuan Z, Zhang Y, Yong S,
Salas-Burgos A, Koomen J, Olashaw N, Parsons JT, Yang XJ, Dent SR,
et al: HDAC6 modulates cell motility by altering the acetylation
level of cortactin. Mol Cell. 27:197–213. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Lafarga V, Aymerich I, Tapia O, Mayor F Jr
and Penelab P: A novel GRK2/HDAC6 interaction modulates cell
spreading and motility. EMBO J. 31:856–869. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Yoshida N, Omoto Y, Inoue A, Eguchi H,
Kobayashi Y, Kurosumi M, Saji S, Suemasu K, Okazaki T, Nakachi K,
et al: Prediction of prognosis of estrogen receptor-positive breast
cancer with combination of selected estrogen-regulated genes.
Cancer Sci. 95:496–502. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Iwata A, Riley BE, Johnston JA and Kopito
RR: HDAC6 and microtubules are required for autophagic degradation
of aggregated huntingtin. J Biol Chem. 280:40282–40292. 2005.
View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Bae HJ, Jung KH, Eun JW, Shen Q, Kim HS,
Park SJ, Shin WC, Yang HD, Park WS, Lee JY and Nam SW: MicroRNA-221
governs tumor suppressor HDAC6 to potentiate malignant progression
of liver cancer. J Hepatol. 63:408–419. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Livaka KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(-Delta Delta C(T)) method. Method. 25:402–408. 2001.
View Article : Google Scholar
|
|
39
|
Rasband WS and Image J US: National
Institutes of Health. Bethesda, Maryland, USA: https://imagej.nih.gov/ij/1997–2016
|
|
40
|
Ma J, Siegel R and Jemal A: Pancreatic
cancer death rates by race among US men and women, 1970–2009. J
Natl Cancer Inst. 105:1694–1700. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Chen W, Zheng R, Zhang S, Zhao P, Li G, Wu
L and He J: Report of incidence and mortality in China cancer
registries, 2009. Chin J Cancer Res. 25:10–21. 2013.PubMed/NCBI
|
|
42
|
Yamamoto H, Itoh F, Iku S, Adachi Y,
Fukushima H, Sasaki S, Mukaiya M, Hirata K and Imai K: Expression
of matrix metalloproteinases and tissue inhibitors of
metalloproteinases in human pancreatic adenocarcinomas:
Clinicopathologic and prognostic significance of matrilysin
expression. J Clin Oncol. 19:1118–1127. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Saito Y, Suzuki H and Hibi T: The role of
microRNAs in gastrointestinal cancers. J Gastroenterol. 44:18–22.
2009. View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Ryu JK, Hong SM, Karikari CA, Hruban RH,
Goggins MG and Maitra A: Aberrant MicroRNA-155 expression is an
early event in the multistep progression of pancreatic
adenocarcinoma. Pancreatology. 10:66–73. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
45
|
Davis BN, Hilyard AC, Nguyen PH, Lagna G
and Hata A: Induction of MicroRNA-221 by platelet-derived growth
factor signaling is critical for modulation of vascular smooth
muscle phenotype. J Biol Chem. 284:3728–3738. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
46
|
Kawaguchi T, Komatsu S, Ichikawa D,
Morimura R, Tsujiura M, Konishi H, Takeshita H, Nagata H, Arita T,
Hirajima S, et al: Clinical impact of circulating miR-221 in plasma
of patients with pancreatic cancer. Br J Cancer. 108:361–369. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
47
|
le Sage C, Nagel R, Egan DA, Schrier M,
Mesman E, Mangiola A, Anile C, Maira G, Mercatelli N, Ciafrè SA, et
al: Regulation of the p27(Kip1) tumor suppressor by miR-221 and
miR-222 promotes cancer cell proliferation. EMBO J. 26:3699–3708.
2007. View Article : Google Scholar : PubMed/NCBI
|
|
48
|
Li J, Lau G, Chen L, Yuan YF, Huang J, Luk
JM, Xie D and Guan XY: Interleukin 23 promotes hepatocellular
carcinoma metastasis via NF-Kappa B induced matrix
metalloproteinase 9 expression. PLoS One. 7:e462642012. View Article : Google Scholar : PubMed/NCBI
|
|
49
|
Lee YS, Lim KH, Guo X, Kawaguchi Y, Gao Y,
Barrientos T, Ordentlich P, Wang XF, Counter CM and Yao TP: The
cytoplasmic deacetylase HDAC6 is required for efficient oncogenic
tumorigenesis. Cancer Res. 68:7561–7569. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
50
|
Shan B, Yao T, Nguyen HT, Zhuo Y, Levy DR,
Klingsberg RC, Tao H, Palmer ML, Holder KN and Lasky JA:
Requirement of HDAC6 for transforming growth factor-1-induced
epithelial-mesenchymal transition. J Biol Chem. 283:21065–21073.
2008. View Article : Google Scholar : PubMed/NCBI
|
